Resistance to EGFR-TKIs remains a significant challenge in managing EGFR-mutated NSCLC effectively; hence, developing novel therapeutics to overcome resistance is still crucial and could tailor treatment strategies to improve patient quality of life and survival [81]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.